Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: APC-8015, Dendreon.

Brian I Rini1

  • 1UCSF Comprehensive Cancer Center, San Francisco, CA 94115, USA.

Current Opinion in Molecular Therapeutics
|March 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Dendreon is developing APC-8015 (Provenge), a dendritic cell therapy for hormone-refractory prostate cancer. This therapy uses a prostate tumor antigen to stimulate the patient's immune system to fight cancer.

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Dendreon is developing APC-8015 (Provenge) in association with the Mayo Clinic.
  • The therapy targets hormone-refractory prostate cancer.
  • Phase III trials began in January 2000.

Purpose of the Study:

  • To evaluate the efficacy of APC-8015 (Provenge) in treating hormone-refractory prostate cancer.
  • To stimulate a patient's immune response against prostate cancer cells.

Main Methods:

  • APC-8015 (Provenge) utilizes a proprietary recombinant antigen from prostatic acid phosphatase.
  • The antigen is combined with the patient's own dendritic cells.
  • The mixture is reinfused into the patient to stimulate an immune response.

Related Experiment Videos

Main Results:

  • Preliminary results were anticipated by the end of 2001.
  • Dendreon planned to file a Biologics License Application (BLA) in 2002.
  • Patents have been awarded covering the prostate tumor antigen, the method of immune stimulation, and the therapeutic composition of APC-8015.

Conclusions:

  • APC-8015 (Provenge) represents a novel approach to prostate cancer treatment by harnessing the patient's immune system.
  • The therapy aims to stimulate the T-cell arm of the immune system to combat cancer.
  • Ongoing clinical trials and patent awards support the development of this dendritic cell therapy.